MicroPort CardioFlow Plans HKEX Main Board IPO with $300 Million Fundraising Target, Enters Pre-roadshow Next Week
MicroPort
High-end Medical Device R&D and Manufacturer
MicroPort CardioFlow
A Provider of High-End Interventional Medical Devices in the Cardiac Valve Field, Engaged in R&D, Manufacturing, Sales, and Related Technical Consulting Services
MicroPort(00853) Spin-off of MicroPort CardioFlow for Independent Listing on the Main Board: According to market sources cited by IFR, MicroPort CardioFlow will conduct pre-roadshow activities next week, aiming to raise approximately USD 300 million (around HKD 2.33 billion). CICC, Citigroup, and JPMorgan serve as joint sponsors. Shareholders of MicroPort Medical are entitled to subscribe for one share of MicroPort CardioFlow for every 200 shares held. The stock went ex-entitlement today, with the register closing on January 19.
Responsible Editor: Zhang Haiying